Spinogenix
Spinogenix is a clinical-stage biopharmaceutical company developing first-in-class once-daily oral small molecules designed to regenerate and correct synapses, targeting ALS, Alzheimer's disease, schizophrenia, Fragile X Syndrome, and glaucoma.
- Company typePrivate
- Founded2016
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Spinogenix does
Spinogenix, Inc. is a clinical-stage biopharmaceutical company founded in 2016 by Stella Sarraf, PhD and headquartered in Los Angeles, California (incorporated in Delaware). The company develops first-in-class once-daily oral small molecules designed to regenerate and correct synapses in the central nervous system, targeting neurodegenerative, neuropsychiatric, and neurodevelopmental conditions characterized by synaptic loss and dysfunction. Its portfolio consists of two core assets: tazbentetol (formerly SPG302), built on the proprietary TAGS™ (Transient Activators of Glutamatergic Synapses) platform, which triggers neurons to produce new glutamatergic synapses and is being studied in amyotrophic lateral sclerosis (ALS), Alzheimer's disease, schizophrenia, and glaucoma; and SPG601, a first-in-class oral modulator of large-conductance calcium-activated potassium (BK) channels being developed for Fragile X Syndrome.
Spinogenix has received FDA Orphan Drug Designation for both candidates (in ALS and FXS), FDA Fast Track Designation for both, and EMA Orphan Drug Designation for both. Tazbentetol demonstrated rapid, sustained cognitive improvement in a Phase 2a Alzheimer's study (nearly 3-point MMSE increase within four weeks, sustained through 24 weeks) and an 82% rate of stable or improved disease trajectory in a Phase 2a ALS study (76% slower progression versus PRO-ACT historical controls through six months). SPG601 completed a Phase 2a in FXS showing reduced abnormal gamma band activity and improved attention/inhibitory control, and a CLARITY Phase 2b/3 trial has been initiated. An FDA-authorized Expanded Access Program provides tazbentetol to up to 200 ALS patients in the United States ineligible for clinical trials.
The company is pre-revenue. Its business model is conventional clinical-stage biopharma economics: generate value through advancement of investigational assets to regulatory approval and subsequent commercialization or out-licensing, with capital sourced from a mix of NIH and Department of Defense grants and exempt securities offerings (a $25 million offering filed in 2024 with $2.8 million sold, followed by a $35 million offering in 2025 with $10.6 million sold to five investors as of November 2025). Distribution is exclusively through clinical trial sites in Australia and the United States and through the Expanded Access Program, with no commercial sales channel. Leadership includes former Merck executives, the former CEO of Clarivate and IHS Markit (Jerre Stead) as Board Chair, and a Scientific Advisory Board anchored by the world's leading glaucoma expert.
Spinogenix firmographics
Firmographics- Name
- Spinogenix
- Legal name
- Spinogenix, Inc.
- Website
- https://spinogenix.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Spinogenix is a clinical-stage biopharmaceutical company developing first-in-class once-daily oral small molecules designed to regenerate and correct synapses, targeting ALS, Alzheimer's disease, schizophrenia, Fragile X Syndrome, and glaucoma.
- Ownership category
- akta.pro rank
Where Spinogenix is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Spinogenix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales
Revenue model
- Pharmaceutical Drug Development: Spinogenix is a clinical-stage biopharmaceutical company with no current revenue. The company is developing two novel therapeutics: tazbentetol (SPG302) for ALS, Alzheimer's disease, and schizophrenia, and SPG601 for Fragile X Syndrome. Revenue generation is contingent on successful clinical development and regulatory approval.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels9 records
Spinogenix product offering
Product offeringCore offering
Spinogenix is developing two investigational, first-in-class oral small molecule therapeutics that restore or correct brain synapses. Tazbentetol (formerly SPG302), built on the proprietary TAGS™ platform, regenerates glutamatergic synapses and is being evaluated in Phase 2 trials for ALS, Alzheimer's disease, and schizophrenia. SPG601 is a BK channel modulator in Phase 2 development for Fragile X Syndrome. Both candidates are administered as once-daily oral pills and are distributed exclusively through clinical trials and an FDA-authorized Expanded Access Program.
Product overview
Spinogenix is a clinical-stage biopharmaceutical company pioneering first-in-class synaptic regenerative and synaptic corrective therapeutics designed to restore depleted synapses and reverse synaptic degeneration and dysfunction. The company's portfolio consists of two novel investigational therapeutics: tazbentetol (SPG302), built on the proprietary TAGS™ (Transient Activators of Glutamatergic Synapses) platform, which triggers neurons to produce new glutamatergic synapses to restore cognitive, motor, and other functions across multiple indications including ALS, Alzheimer's disease, schizophrenia, and glaucoma; and SPG601, a BK channel modulator that corrects specific synaptic dysfunctions in Fragile X Syndrome. Both therapeutics are administered as once-daily oral tablets.
Differentiator
Problem solved
Functional benefit
Products and services
- Tazbentetol (formerly SPG302) First-in-class, once-daily oral small molecule therapeutic built on the proprietary TAGS™ (Transient Activators of Glutamatergic Synapses) platform. Designed to trigger neurons to produce new glutamatergic synapses and restore cognitive, motor, and other functions in patients with ALS, Alzheimer's disease, schizophrenia, and related neurodegenerative/neuropsychiatric conditions. Currently distributed exclusively through clinical trials and an FDA-authorized Expanded Access Program for ALS.
- SPG601 First-in-class, once-daily oral small molecule designed to modulate large-conductance calcium-activated potassium (BK) channels to correct specific synaptic dysfunctions underlying core symptoms of Fragile X Syndrome, including cognitive, emotional, and sensory impairments. Currently administered through clinical trials.
Quantifiable outcome
- 82% of ALS patients treated with tazbentetol showed stable or improved rate of decline at end of treatment
- +3 more outcomes
Companies that use Spinogenix
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
Spinogenix technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Spinogenix partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Cincinnati Children's HospitalcoreDr. Craig Erickson, Spinogenix Chief Medical Advisor, serves as principal investigator at Cincinnati Children's Hospital within the IMPACT network, a 10-site international research consortium. The hospital received a $17.25 million, five-year grant from ARIA initiative to study EEG biomarkers and genomic analysis for precision medicine approaches to autism, with Dr. Erickson's work including Spinogenix's SPG601 compound research.
- University of California San Diego (Shiley Eye Institute)minorDr. Robert N. Weinreb joined Spinogenix's Scientific Advisory Board as Chair and Distinguished Professor of Ophthalmology at UC San Diego and Director of the Shiley Eye Institute. Dr. Weinreb is recognized as the #1 expert in world glaucoma and supports the company's glaucoma program development.
- University of Southern CaliforniaminorDr. Justin K. Ichida, Associate Professor at Keck School of Medicine at USC, serves on Spinogenix's Scientific Advisory Board. His research focuses on neurodegenerative diseases including ALS and frontotemporal dementia, bringing expertise in stem cell biology and regenerative medicine.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Spinogenix competitors and assessment
Company assessmentDirect peers
- Denali Therapeutics: Clinical-stage biotech developing small molecule and biologic therapeutics for neurodegeneration including ALS, Alzheimer's, and Parkinson's. Most directly comparable peer given overlapping neurological indications and clinical stage.
- Anavex Life Sciences: Clinical-stage biopharmaceutical company developing oral small molecules for Alzheimer's disease, Rett syndrome, and other neurodegenerative diseases. Direct peer given similar CNS indications and small molecule approach.
- Sage Therapeutics: CNS-focused biopharmaceutical company with FDA-approved Zurzuvae for postpartum depression and pipeline targeting neurological/psychiatric disorders. Direct peer given CNS focus and small molecule development.
- Prothena Corporation: Clinical-stage biotech developing therapies for neurodegenerative diseases including Parkinson's, Alzheimer's, and ALS. Comparable in therapeutic area focus and clinical stage.
- Neumora Therapeutics: Clinical-stage biopharma developing precision medicines for brain diseases including schizophrenia and neurodegenerative disorders. Comparable clinical stage and CNS therapeutic focus.
Broad incumbents
- Acadia Pharmaceuticals: Established CNS-focused biopharma with FDA-approved products including Nuplazid for Parkinson's psychosis and Daybue for Rett syndrome. Broader incumbent with commercial CNS portfolio, overlapping with Spinogenix's targeted indications.
- Axsome Therapeutics: CNS-focused biopharma with FDA-approved Auvelity for major depressive disorder and pipeline in Alzheimer's agitation and other neurological conditions. Broader CNS incumbent with overlapping neurological indications.
Emerging players
- BioXcel Therapeutics: Clinical-stage biopharma using AI to develop CNS therapies with focus on agitation in dementia and other neurological conditions. Comparable as clinical-stage CNS drug developer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Spinogenix social profiles
Digital presenceSpinogenix compliance and trust
Trust signalCompliance6 records
Spinogenix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spinogenix leadership team
Management profileNumber of profiles
Profiles7 records
Spinogenix funding detail
Funding detailFunding overview
Funding rounds7 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spinogenix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spinogenix
What does Spinogenix do?
Spinogenix is developing two investigational, first-in-class oral small molecule therapeutics that restore or correct brain synapses. Tazbentetol (formerly SPG302), built on the proprietary TAGS™ platform, regenerates glutamatergic synapses and is being evaluated in Phase 2 trials for ALS, Alzheimer's disease, and schizophrenia. SPG601 is a BK channel modulator in Phase 2 development for Fragile X Syndrome. Both candidates are administered as once-daily oral pills and are distributed exclusively through clinical trials and an FDA-authorized Expanded Access Program.
Is Spinogenix a public or private company?
Spinogenix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Spinogenix founded?
Spinogenix was founded in 2016. It employs 1 to 10 people.
Where is Spinogenix based?
Spinogenix is headquartered in San Diego, United States, in the North America region.
How does Spinogenix make money?
One revenue line is on record: pharmaceutical Drug Development.
Who are Spinogenix's main competitors?
Direct peers on record are Denali Therapeutics, Anavex Life Sciences, Sage Therapeutics, Prothena Corporation and Neumora Therapeutics. Broad incumbents are Acadia Pharmaceuticals and Axsome Therapeutics. BioXcel Therapeutics is listed as an emerging player.
Does Spinogenix have an API?
No public API is recorded for Spinogenix.